365 related articles for article (PubMed ID: 27894399)
1. Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Wang XT; Li P; Xu TS; Ding R; Zhang X; Bi LQ
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):44-50. PubMed ID: 27894399
[TBL] [Abstract][Full Text] [Related]
2. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
3. Effects of IL-34 on the secretion of RANKL/OPG by fibroblast-like synoviocytes and peripheral blood mononuclear cells in rheumatoid arthritis.
Cui MY; Li X; Lei YM; Xia LP; Lu J; Shen H
Eur Cytokine Netw; 2019 Jun; 30(2):67-73. PubMed ID: 31486401
[TBL] [Abstract][Full Text] [Related]
4. Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway.
Niu HQ; Zhao WP; Zhao XC; Luo J; Qin KL; Chen KL; Li XF
Int Immunopharmacol; 2018 Aug; 61():45-53. PubMed ID: 29803913
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.
Li Y; Li D; Li Y; Wu S; Jiang S; Lin T; Xia L; Shen H; Lu J
Osteoporos Int; 2016 Apr; 27(4):1537-1546. PubMed ID: 26572759
[TBL] [Abstract][Full Text] [Related]
6. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
Wang X; Ma C; Li P; Zhao F; Bi L
Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138
[TBL] [Abstract][Full Text] [Related]
7. Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis.
Ainola M; Mandelin J; Liljeström M; Konttinen YT; Salo J
Clin Exp Rheumatol; 2008; 26(2):240-6. PubMed ID: 18565244
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human endostatin inhibits TNF-alpha-induced receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes in mice with adjuvant arthritis.
Gao QF; Zhang XH; Yuan FL; Zhao MD; Li X
Cell Biol Int; 2016 Dec; 40(12):1340-1348. PubMed ID: 27730697
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients.
Wei Y; Sun X; Hua M; Tan W; Wang F; Zhang M
Biomed Res Int; 2015; 2015():214683. PubMed ID: 26273599
[TBL] [Abstract][Full Text] [Related]
10. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
11. CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis.
Tsushima H; Okazaki K; Ishihara K; Ushijima T; Iwamoto Y
Arthritis Res Ther; 2015 Feb; 17(1):31. PubMed ID: 25811130
[TBL] [Abstract][Full Text] [Related]
12. A combination of sinomenine and methotrexate reduces joint damage of collagen induced arthritis in rats by modulating osteoclast-related cytokines.
Sun Y; Yao Y; Ding CZ
Int Immunopharmacol; 2014 Jan; 18(1):135-41. PubMed ID: 24287449
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis.
Wen H; Liu Y; Li J; Wei D; Liu D; Zhao F
Clin Exp Rheumatol; 2018; 36(5):798-805. PubMed ID: 29465363
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-13 reduces bone erosion in rheumatoid arthritis by up-regulating osteoprotegerin expression in fibroblast-like synoviocytes : an in vitro and in vivo study.
Chen Z; Cheng Z; Tang Z; Li M; Tang X; Zhang H; Sun L
Clin Exp Rheumatol; 2023 Nov; 41(11):2151-2161. PubMed ID: 36995338
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
[TBL] [Abstract][Full Text] [Related]
16. Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.
Yao Y; Ding CZ; Fang Y
Rheumatol Int; 2013 Jul; 33(7):1845-53. PubMed ID: 23334376
[TBL] [Abstract][Full Text] [Related]
17. Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate.
Revu S; Neregård P; af Klint E; Korotkova M; Catrina AI
Arthritis Res Ther; 2013; 15(6):R205. PubMed ID: 24295447
[TBL] [Abstract][Full Text] [Related]
18. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1β on rheumatoid arthritis fibroblast-like synoviocytes.
Bergström B; Carlsten H; Ekwall AH
Arthritis Res Ther; 2018 Mar; 20(1):49. PubMed ID: 29554943
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
Świerkot J; Gruszecka K; Matuszewska A; Wiland P
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
